查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830983

发炎性肠道疾病治疗市场

Inflammatory Bowel Disease Treatment Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

发炎性肠道疾病治疗的市场价值预计将从 2024 年的 249.5 亿美元增加到 2031 年的 316.7 亿美元，2025 年至 2031 年期间的预估复合年增长率为 3.50%。

市场洞察与分析师观点：发炎性肠道疾病 (IBD) 是指一种影响胃肠道的慢性发炎性疾病，包括克隆氏症和溃疡性结肠炎等疾病。这些疾病会导致消化道内壁发炎，进而引发腹痛、腹泻、疲劳和体重减轻等症状。治疗的目标是透过药物治疗、改变生活方式以及偶尔的手术来缓解发炎、控制症状并避免併发症。持续的医疗照护和监测对于管理 IBD、维持缓解和提高生活品质至关重要。发炎性肠道疾病治疗市场的成长主要得益于克隆氏症和溃疡性结肠炎发病率的上升以及产品上市数量的增加。本报告概述了基于发炎性肠道疾病治疗市场当前趋势及其在预测期内的预期影响的成长机会。预计未来几年，技术创新将为发炎性肠道疾病治疗市场带来重大趋势。此外，透过持续研究和政府支持措施开发新的治疗方法可能会进一步刺激市场成长。

成长因素与挑战：克隆氏症是一种多方面的慢性疾病，主要影响消化系统。根据美国国家医学图书馆的数据，2023年每10万人中有825例发炎性肠道疾病（IBD），其中包括410例克隆氏症和414例溃疡性结肠炎及IBD-u。 IBD的盛行率为0.82%，2023年约有322,600名加拿大人被诊断为IBD。由于诊断程序要求禁食、治疗期间的饮食限制以及厌食或疾病本身引起的营养需求改变导致的食慾不振，胃肠道疾病患者面临更高的营养不良风险。因此，肠内营养通常被推荐用于这些患者，因为它是输送必需营养素的首选方法。因此，克隆氏症和溃疡性结肠炎盛行率的不断上升推动了发炎性肠道疾病治疗市场的成长。

常见的胃肠道疾病包括克隆氏症、创伤性胃肠道疾病、肠阻塞（BO）、显微镜结肠炎、短肠症候群和溃疡性结肠炎。 Healthline 2021年的一篇文章指出，全球约有40%的人口患有功能性胃肠道疾病。加拿大消化健康基金会报告称，数百万加拿大人患有消化系统疾病，每年约有2,000万加拿大人（即每3人中就有2人）患有消化系统疾病。

相反，发炎性肠道疾病 (IBD) 治疗的高昂费用给 IBD 治疗市场带来了重大挑战。药物、频繁就诊和手术相关的费用会给患者和医疗保健系统带来沉重的经济负担。这一成本因素往往会限制许多 IBD 患者获得最佳护理和创新治疗的机会。解决可负担性和可近性问题对于改善这种慢性疾病患者的治疗效果和生活品质至关重要。因此，高昂的治疗费用阻碍了发炎性肠道疾病治疗市场的成长。

策略性洞察报告细分和范围：发炎性肠道疾病治疗市场的分析是透过检查以下细分市场进行的：药物类别、疾病适应症和配销通路。从地理上讲，发炎性肠道疾病治疗市场分为北美（美国、加拿大和墨西哥）、欧洲（英国、德国、法国、义大利、西班牙和欧洲其他地区）、亚太地区（中国、日本、印度、澳洲、韩国和亚太其他地区）、中东和非洲（阿联酋、沙乌地阿拉伯、南非和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲（巴西、阿根廷和南美洲和其他地区）。

細項分析：基于药物类别的洞察。依药物类别，市场分为生物製剂、氨基水杨酸盐、皮质类固醇和其他药物。生物製剂在2023年占据了发炎性肠道疾病治疗市场的最大份额，预计在2023年至2031年期间将呈现最高的复合年增长率。

基于疾病适应症的洞察：就疾病适应症而言，发炎性肠道疾病治疗市场分为克隆氏症和溃疡性结肠炎。预计到2031年，克罗恩病领域将占据相当大的市场。

基于分销管道的洞察：就分销管道而言，市场分为医院药房、零售药房和线上药房。预计到2031年，医院药局将在发炎性肠道疾病治疗市场中占据相当大的份额。

发炎性肠道疾病治疗市场报告范围区域分析：发炎性肠道疾病治疗市场报告的地理范围包括北美、欧洲、亚太地区、中东和非洲以及南美和中美。 2023 年，北美占据了最大的市场份额，美国凭藉其巨大的收入份额在该地区处于领先地位。美国发炎性肠道疾病治疗市场的成长归因于发炎性疾病的盛行率上升、主要市场参与者的存在及其策略性倡议。增强的支付解决方案、高治疗率、创新药物处方的增加、持续的研究努力以及有利的政府倡议也支持了美国和其他北美国家的发炎性肠道疾病治疗市场。克罗恩病和结肠炎基金会是一个致力于推进旨在治疗结肠炎和克隆氏症的临床和转化研究的着名组织。

竞争格局与关键公司：本报告中对发炎性肠道疾病治疗市场的预测可以帮助利害关係人制定成长策略。发炎性肠道疾病治疗市场报告中介绍的关键公司包括艾伯维公司、武田製药有限公司、辉瑞公司、百健公司、诺华公司、礼来公司、优时比公司、CELLTRION公司、默克公司和强生服务公司。这些公司专注于扩大产品供应，以满足日益增长的全球消费者需求。他们的国际影响力使他们能够服务广泛的客户群，从而促进其市场扩张。

目录

第一章：简介

第 2 章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：发炎性肠道疾病治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：发炎性肠道疾病治疗市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：发炎性肠道疾病治疗市场－全球市场分析

  • 发炎性肠道疾病治疗－全球市场概览
  • 发炎性肠道疾病治疗－全球市场及2031年预测

第七章：发炎性肠道疾病治疗市场 - 收入分析 - 按药物类别，2021-2031 年

  • 概述
  • 氨基水杨酸盐
  • 免疫调节剂
  • TNF抑制剂
  • 皮质类固醇

第 8 章：发炎性肠道疾病治疗市场 - 收入分析 - 按疾病适应症，2021-2031 年

  • 概述
  • 克罗恩病
  • 溃疡性结肠炎

第九章：发炎性肠道疾病治疗市场-收入分析-按配销通路，2021-2031

  • 概述
  • 医院药房
  • 网路药局
  • 零售药局

第 10 章：发炎性肠道疾病治疗市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 13 章：发炎性肠道疾病治疗市场 - 主要公司简介

  • Pfizer Inc.
  • Novartis AG
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Johnson and Johnson (Janssen Global Services, LLC)
  • CELGENE CORPORATION
  • Bausch Health Companies Inc.
  • UCB, Inc.
  • COSMO PHARMACEUTICALS
  • Gilead Sciences

第 14 章：附录

简介目录
Product Code: TIPRE00003491

The market value for inflammatory bowel disease treatment is expected to increase from US$ 24.95 billion in 2024 to US$ 31.67 billion by 2031, with a projected CAGR of 3.50% during the period from 2025 to 2031.

Market Insights and Analyst Perspective:Inflammatory bowel disease (IBD) refers to a chronic inflammatory disorder affecting the gastrointestinal tract, which includes conditions such as Crohn's disease and ulcerative colitis. These diseases lead to inflammation of the digestive tract lining, resulting in symptoms like abdominal pain, diarrhea, fatigue, and weight loss. The goal of treatment is to alleviate inflammation, manage symptoms, and avert complications through medications, lifestyle modifications, and occasionally surgery. Ongoing medical care and monitoring are essential for managing IBD to maintain remission and enhance quality of life. The growth of the Inflammatory Bowel Disease Treatment Market is primarily driven by the increasing incidence of Crohn's disease and ulcerative colitis, along with a rise in product launches. This report outlines growth opportunities based on current trends in the Inflammatory Bowel Disease Treatment Market and their anticipated effects during the forecast period. Technological innovations are expected to introduce significant trends in the Inflammatory Bowel Disease Treatment Market in the upcoming years. Additionally, the development of new treatments through ongoing research and supportive government initiatives is likely to further stimulate market growth.

Growth Factors and Challenges:Crohn's disease is a multifaceted, chronic condition that mainly impacts the digestive system. According to the National Library of Medicine, there were 825 cases of IBD per 100,000 individuals in 2023, which includes 410 cases of Crohn's disease and 414 cases of ulcerative colitis and IBD-u. With a prevalence rate of 0.82%, approximately 322,600 Canadians were diagnosed with IBD in 2023. Patients suffering from gastrointestinal diseases face a heightened risk of nutritional decline due to the fasting requirements of diagnostic procedures, dietary restrictions for treatment, and appetite loss stemming from anorexia or altered nutritional needs caused by the disease itself. Consequently, enteral nutrition is often recommended for these patients, as it is the preferred method for delivering essential nutrients. Thus, the increasing prevalence of Crohn's disease and ulcerative colitis propels the growth of the Inflammatory Bowel Disease Treatment Market.

Common gastrointestinal diseases include Crohn's disease, trauma-related gastrointestinal disorders, bowel obstruction (BO), microscopic colitis, short bowel syndrome, and ulcerative colitis. An article published by Healthline in 2021 indicated that approximately 40% of the global population is affected by functional gastrointestinal disorders. The Canadian Digestive Health Foundation reports that millions of Canadians suffer from digestive diseases, with around 20 million Canadians, or 2 out of every 3 individuals, experiencing digestive disorders annually.

Conversely, the high costs associated with treating inflammatory bowel disease (IBD) present a significant challenge in the IBD treatment market. The expenses related to medications, frequent hospital visits, and surgeries can impose a substantial financial burden on patients and healthcare systems. This cost factor often restricts access to optimal care and innovative treatments for many individuals living with IBD. Addressing issues of affordability and accessibility is vital for enhancing outcomes and quality of life for patients affected by this chronic condition. Therefore, the high treatment costs impede the growth of the Inflammatory Bowel Disease Treatment Market.

Strategic Insights

Report Segmentation and Scope:The analysis of the Inflammatory Bowel Disease Treatment Market has been conducted by examining the following segments: drug class, disease indication, and distribution channel. Geographically, the Inflammatory Bowel Disease Treatment Market is divided into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:Insights Based on Drug ClassBy drug class, the market is categorized into biologics, aminosalicylates, corticosteroids, and others. The biologics segment accounted for the largest share of the Inflammatory Bowel Disease Treatment Market in 2023 and is expected to exhibit the highest CAGR from 2023 to 2031.

Insights Based on Disease IndicationIn terms of disease indication, the Inflammatory Bowel Disease Treatment Market is divided into Crohn's disease and ulcerative colitis. The Crohn's disease segment is projected to capture a significant market share by 2031.

Insights Based on Distribution Channel

Regarding distribution channels, the market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment is expected to hold a substantial share of the Inflammatory Bowel Disease Treatment Market by 2031.

Inflammatory Bowel Disease Treatment Market Report ScopeRegional Analysis:The geographic scope of the Inflammatory Bowel Disease Treatment Market report includes North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. In 2023, North America held the largest market share, with the US leading the market in this region due to its significant revenue share. The growth of the Inflammatory Bowel Disease Treatment Market in the US is attributed to the rising prevalence of inflammatory diseases, the presence of major market players, and their strategic initiatives. Enhanced payment solutions, high treatment rates, increased prescriptions of innovative medications, continuous research efforts, and favorable government initiatives also support the Inflammatory Bowel Disease Treatment Market in the US and other North American countries. The Crohn's & Colitis Foundation is a prominent organization dedicated to advancing clinical and translational research aimed at curing colitis and Crohn's disease.

Competitive Landscape and Key Companies:The forecast for the Inflammatory Bowel Disease Treatment Market presented in this report can assist stakeholders in formulating their growth strategies. Key companies profiled in the Inflammatory Bowel Disease Treatment Market report include AbbVie Inc, Takeda Pharmaceutical Company Limited, Pfizer Inc, Biogen, Novartis AG, Lilly, UCB S.A., CELLTRION INC., Merck & Co., Inc., and Johnson & Johnson Services, Inc. These companies are focused on expanding their product offerings to meet the growing global consumer demand. Their international presence enables them to serve a wide customer base, thereby facilitating their market expansion.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Inflammatory Bowel Disease Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Inflammatory Bowel Disease Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Inflammatory Bowel Disease Treatment Market - Global Market Analysis

  • 6.1 Inflammatory Bowel Disease Treatment - Global Market Overview
  • 6.2 Inflammatory Bowel Disease Treatment - Global Market and Forecast to 2031

7. Inflammatory Bowel Disease Treatment Market - Revenue Analysis (USD Million) - By Drug Class, 2021-2031

  • 7.1 Overview
  • 7.2 Aminosalicyclates
  • 7.3 Immunomodulators
  • 7.4 TNF Inhibitors
  • 7.5 Corticosteroids

8. Inflammatory Bowel Disease Treatment Market - Revenue Analysis (USD Million) - By Disease Indication, 2021-2031

  • 8.1 Overview
  • 8.2 Crohn's Disease
  • 8.3 Ulcerative Colitis

9. Inflammatory Bowel Disease Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 9.1 Overview
  • 9.2 Hospital Pharmacy
  • 9.3 Online Pharmacy
  • 9.4 Retail Pharmacy

10. Inflammatory Bowel Disease Treatment Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Inflammatory Bowel Disease Treatment Market Overview
    • 10.1.2 North America Inflammatory Bowel Disease Treatment Market Revenue and Forecasts to 2031
    • 10.1.3 North America Inflammatory Bowel Disease Treatment Market Revenue and Forecasts and Analysis - By Drug Class
    • 10.1.4 North America Inflammatory Bowel Disease Treatment Market Revenue and Forecasts and Analysis - By Disease Indication
    • 10.1.5 North America Inflammatory Bowel Disease Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America Inflammatory Bowel Disease Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Inflammatory Bowel Disease Treatment Market
        • 10.1.6.1.1 United States Inflammatory Bowel Disease Treatment Market, by Drug Class
        • 10.1.6.1.2 United States Inflammatory Bowel Disease Treatment Market, by Disease Indication
        • 10.1.6.1.3 United States Inflammatory Bowel Disease Treatment Market, by Distribution Channel
      • 10.1.6.2 Canada Inflammatory Bowel Disease Treatment Market
        • 10.1.6.2.1 Canada Inflammatory Bowel Disease Treatment Market, by Drug Class
        • 10.1.6.2.2 Canada Inflammatory Bowel Disease Treatment Market, by Disease Indication
        • 10.1.6.2.3 Canada Inflammatory Bowel Disease Treatment Market, by Distribution Channel
      • 10.1.6.3 Mexico Inflammatory Bowel Disease Treatment Market
        • 10.1.6.3.1 Mexico Inflammatory Bowel Disease Treatment Market, by Drug Class
        • 10.1.6.3.2 Mexico Inflammatory Bowel Disease Treatment Market, by Disease Indication
        • 10.1.6.3.3 Mexico Inflammatory Bowel Disease Treatment Market, by Distribution Channel
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Inflammatory Bowel Disease Treatment Market - Key Company Profiles

  • 13.1 Pfizer Inc.
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Novartis AG
  • 13.3 AbbVie Inc.
  • 13.4 Takeda Pharmaceutical Company Limited
  • 13.5 Johnson and Johnson (Janssen Global Services, LLC)
  • 13.6 CELGENE CORPORATION
  • 13.7 Bausch Health Companies Inc.
  • 13.8 UCB, Inc.
  • 13.9 COSMO PHARMACEUTICALS
  • 13.10 Gilead Sciences

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud